News

Business Wire4y
Incyte Announces Positive CHMP Opinion for Pemigatinib for the Treatment of Adults With Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma With ...
About FIGHT-202 The FIGHT-202 Phase 2, open-label, multicenter study (NCT02924376) is evaluating the safety and efficacy of pemigatinib – a selective fibroblast growth factor receptor (FGFR ...
Business Wire3y
StemCultures Introduces FGF2 DISC™ Devices for Precise Control of Fibroblast Growth Factor 2 Concentration during Cell Culture
today announced the launch of FGF2 DISC™ devices which consist of biodegradable StemBeads® loaded with recombinant human fibroblast growth factor 2 (FGF2) embedded in an inert non-biodegradable ...
The New England Journal of Medicine4y
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
AKT, fibroblast growth factor receptor (FGFR), and human epidermal growth factor receptor 2 (HER2) represent overexpression, amplification, or mutation implicated in either endocrine therapy or ...
The New England Journal of Medicine16y
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Fibroblast growth factor 23 (FGF-23) is a hormone that increases ... per deciliter [1.1 to 1.4 mmol per liter]) (hazard ratio, 1.2; 95% confidence interval [CI], 1.1 to 1.4).